Nischal Raya, MD
Internal Medicine · Chicago, ILNPI 1326429747
Payments from drug & device makers
Across 224 payments — averaging $169.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$34K
- AstraZeneca$1K
- GSK$776
- Regeneron Healthcare Solutions, Inc.$379
- Sanofi$308
- Amgen$237
- plus $1K from 21 others
What the payments were for
- Travel & lodging$5621%
- Food & beverage$5,21114%
- Education$32,14885%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 34 | $33,959 |
| AstraZeneca(2 entities) | 42 | $1,116 |
| GSK | 52 | $776 |
| Regeneron Healthcare Solutions, Inc. | 18 | $379 |
| Sanofi | 11 | $308 |
| Amgen | 11 | $237 |
| Boehringer Ingelheim | 8 | $184 |
| Grifols USA, LLC | 7 | $150 |
| Verona Pharma, Inc. | 8 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Merck | 4 | $73 |
| Pulmonx Corporation | 3 | $63 |
| Mylan Specialty L.p. | 2 | $43 |
| Johnson & Johnson | 1 | $39 |
| Electromed, Inc. | 4 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Melinta Therapeutics, LLC | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $24 |
| United Therapeutics Corporation | 1 | $22 |
| Insmed, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$33,612
- FASENRA$338
- DUPIXENT$115
How this compares
$37,921 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 245 | $189,565 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $130,234 |
| Dupixent PenDupilumab | 27 | $103,503 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $53,628 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $51,609 |
| Spiriva RespimatTiotropium Bromide | 74 | $45,759 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $29,724 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $20,119 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 461 | $11,533 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,665 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $4,043 |
| Montelukast Sodium | 404 | $3,658 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,642 |
| Azithromycin | 112 | $1,031 |
| Prednisone | 254 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $776 | $263,312385 claims |
| Grifols USA, LLCProlastin C | $150 | $130,23413 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $184 | $75,483135 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,116 | $56,27475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.